Nutritional priorities to support GLP
Conclusions Evidence-based nutritional and lifestyle strategies play a pivotal role to address key challenges around GLP-1 treatment of obesity , making clinicians more effective in advancing their patients' health.
Glucagon-like peptide 1 receptor agonists and combination medications (hereafter collectively referred to as GLP-1s ) are shifting the treatment landscape for obesity . However, real-world challenges and limited clinician and public knowledge on nutritional and lifestyle interventions can limit GLP-1 efficacy, equitable results, and cost-effectiveness.
WHO guideline on the use of glucagon
A separate WHO guideline is under development on the management of obesity in children and adolescents. This guideline aims to support the safe, equitable and appropriate inclusion of pharmacological therapy for adults as part of comprehensive obesity chronic care programmes.
GLP-1 therapies, including both single and combination agents, have emerged as powerful tools in the management of obesity , demonstrating average placebo-adjusted weight reductions of 5-18% in clinical trials, along with improvements in metabolic, functional and cardiovascular outcomes. However, sustaining these benefits over time and maximizing patient outcomes require comprehensive care ...
Nutritional and lifestyle supportive care recommendations for ...
Nutritional priorities to support GLP-1 therapy for obesity : a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society
The rise of GLP-1 obesity treatment has transformed how clinicians approach patients with both obesity and diabetes. These therapies, originally developed for glucose control, now show robust benefits in weight management.
WHO Guideline on GLP
This Special Communication summarizes the WHO guideline on the management of obesity with GLP-1 therapies in adults and calls on nations to ensure equitable access to obesity prevention and management interventions.
Glucagon-like peptide-1 ( GLP-1 ) therapies are highly effective for weight loss and metabolic improvement in obesity and type 2 diabetes management. However, their use poses clinical challenges, including loss of lean muscle mass and gastrointestinal side effects, both of which may affect adherence and long-term outcomes.
WHO Guideline on GLP
To the Editor The recent WHO guideline on use of GLP-1 therapies by Dr Celletti and colleagues1 framed obesity as a chronic, relapsing disease requiring sustained treatment. While this guideline focused on the general adult population, we contend that its proposed "highest need" prioritization...
Abstract Glucagon-like peptide 1 (GLP-1)-based therapies, such as semaglutide and tirzepatide, represent highly effective treatment options for people with type 2 diabetes and obesity , enabling effective control of glucose and weight loss, while reducing cardiovascular and renal morbidity and mortality.